Mutant TNFalpha negatively regulates human breast cancer stem cells from MCF7 in vitro

Yaochen Li1, Linghong Kong, Ye Yang

  • 1Department of Microbiology and Immunology, The Key Immunopathology Laboratory of Guangdong province, Shantou University Medical College, Shantou, Guangdong, China.

Cancer Biology & Therapy
|September 21, 2007
PubMed

Insights

Mutant TNFalpha (Tumor Necrosis Factor alpha) effectively reduces breast cancer stem cell self-renewal and increases apoptosis. This suggests its potential as a novel therapeutic for breast cancer treatment.

Area of Science:

  • Oncology
  • Cell Biology
  • Immunology

Background:

  • Breast cancer stem cells (BCSCs) are crucial for tumor recurrence and metastasis.
  • Targeting BCSCs is a key strategy for developing effective breast cancer cures.
  • MCF7 cell line is a common model for studying human breast cancer.

Purpose of the Study:

  • To investigate the effect of mutant TNFalpha (Tumor Necrosis Factor alpha) on human breast cancer stem cells.
  • To characterize the biological features of MCF7-derived side population (SP) cells in vitro.
  • To explore the therapeutic potential of mutant TNFalpha in breast cancer treatment.

Main Methods:

  • MCF7 side population (SP) cells were isolated using Fluorescence-Activated Cell Sorting (FACS).
  • Cancer stem cell characteristics and TNFR-p55/TNFR-p75 expression were assessed by RT-PCR.
  • Apoptosis and self-renewal were measured after treatment with mutant TNFalpha (Mt rh471) and wild-type TNFalpha (Wt rhTNFalpha).

Main Results:

  • MCF7 SP cells exhibited cancer stem cell markers but lacked multidrug resistance transporters.
  • Mt rh471 TNFalpha significantly decreased SP cell self-renewal and increased apoptosis.
  • Blocking TNFR-p55 abolished the inhibitory effect of Mt rh471 TNFalpha on self-renewal, unlike Wt rhTNFalpha.

Conclusions:

  • Mutant TNFalpha (Mt rh471) acts as a negative regulator of breast cancer stem-like cells.
  • Mt rh471 TNFalpha induces apoptosis in SP cells, potentially through TNFR-p55.
  • This mutant TNFalpha shows promise for clinical application in breast cancer therapy.

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...